Back to YC Companies
ParcelBio
Winter 2024
Active
Elevated mRNA for transformative medicines.
6 people View on YC
ParcelBio at a glance
- Y Combinator batch
- Winter 2024
- Status
- Active
- Industry
- Healthcare
- Team size
- 6 people
- Location
- Not recorded
- Website
- Not recorded
Every field above comes from the Y Combinator company record. Nothing is estimated.
About ParcelBio
ParcelBio is engineering a new class of mRNA medicines designed to deliver unprecedented potency and durability. Its proprietary APEXm™ platform uses novel RNA domains to enhance protein expression and extend activity, enabling therapies that reach the thresholds required for meaningful, and potentially curative, clinical outcomes. The company is advancing programs in autoimmune disease, oncology, and encoded protein therapeutics.
Tags:
Gene Therapy
Synthetic Biology
Biotech
Therapeutics
Drug discovery